JavaTide

JavaTide is a preclinical-stage biotechnology company specializing in the development of next-generation peptide therapeutics using its proprietary cyclotide platform. Founded as a spin-out from the University of Queensland, the company leverages the pioneering research of Professor David Craik to create ultra-stable circular peptides. These cyclotides are engineered to overcome the traditional limitations of linear peptides, offering enhanced proteolytic stability and the potential for oral bioavailability. JavaTide's pipeline focuses on re-engineering naturally occurring cyclic frameworks to address challenging targets in metabolic disorders, chronic pain, and inflammatory diseases. The company aims to bridge the gap between small molecules and biologics by providing highly specific, stable, and potent therapeutic candidates.